Pharmaceuticals & Biotech Spanish Community

Situación financiera sólida : Patrimonio neto > 60% del balance, deuda controlada. Beneficio coyunturalmente bajo : impacto no estructural.Read more

Recent Financial Performance In H1 2025, Rovi’s net profit dropped by 10% to €39.7 million. The decline was mainly due to reduced third-party manufacturing, especially COVID-19 vaccine production.Read more

Grifols could benefit as more people rely on plasma-based medicines, especially as populations age and healthcare access grows in emerging markets. But the story also hinges on whether it can keep improving how it collects and produces plasma while navigating debt, pricing pressure, and tougher rules around U.S. plasma sourcing.Read more

Faes Farma is reshaping its business by pushing deeper into Latin America and adding a new eye-care line through recent acquisitions, aiming to broaden where its growth comes from. The big question is whether these new products and regions can outpace the slowdown in its older allergy brand and the extra costs that come with expansion.Read more

Almirall’s skin-health drugs are gaining traction faster than many expect, and new uses could widen the group of patients who might benefit. But the story depends heavily on just a few medicines and on Europe’s tough pricing rules, so any shift in competition or regulation could change the outlook.Read more

Almirall is leaning hard into new skin treatments, and early momentum from its latest medicines and partnerships could reshape its growth story over the next few years. The catch is that a lot rides on just a couple of products, while rising development costs and a weak U.S. business could hold back progress.Read more

PharmaMar’s business leans heavily on one cancer drug, and growing pressure from governments and copycat medicines could make it harder to keep prices and profits up. See why its future may hinge on proving new uses for that drug and bringing more treatments to market before competition catches up.Read more

A Spain-based cancer drugmaker bets on hard-to-copy compounds from the sea, and early signs suggest its lead medicine could gain ground faster in Europe and new international markets than many expect. But the story comes with a big catch: the business leans heavily on just a few drugs while competition, partner setbacks, and regulators could quickly change the outlook.Read more

Grifols rides a growing need for plasma-based medicines, and its push to expand and modernize its collection centers could help it make more product and run more efficiently. But pricing pressure, currency swings, and heavy debt could squeeze results if conditions in key markets turn against it.Read more